***Background.*** There is paucity of data about safety, tolerability and efficacy of colistin in neonatal sepsis. Hence this study was conducted two separate neonatal and pediatric cardiac surgical intensive care units in a tertiary care hospital in Mumbai, India.

***Methods.*** This is a retrospective study in which the case records of all neonates aged less than 1 month who received colistin for at least 5 days in the years 2011-2013 were included. Data including age, sex, gestational age, birth weight, risk factors for sepsis, age at initiation of colistin, dose and duration of therapy, companion drugs, indication for treatment (definitive/ empirical) and outcomes was abstracted and analyzed. Therapy was considered empirical when cultures were negative and definitive when peripheral blood cultures or endotracheal cultures (in the setting of health care associated pneumonia) were positive.

***Results.*** A total of 32 neonates were administered colistin during the study period (3 in 2011, 12 in 2012 and 17 in 2013). Fifteen were term babies and seventeen were preterm. Risk factors for sepsis included prematurity in seventeen and surgery for congenital heart disease in the rest. The mean gestational age of the preterm babies was 30 weeks (range 24-36) and the mean birth weight was 2 kg (range 660 gms-3.5 kg). The average post natal age at starting colistin was 13 days (range 5-30 days) and average duration of therapy was 13 days (range 5-22 days). The most common companion drug was meropenem (25/32 babies) and median dose of colistin was 6 mg/kg/day (range 4-12 mg/kg/day). Therapy was empirical in 15/32 patients and definite in 17/32 (blood stream infection in 12 and pneumonia in 5). Of the patients who were culture positive, eight had infection with carbapenem resistant strains of klebsiella (4), acinetobacter (2) and pseudomonas (2). Only 2 babies died; both having infection with carbapenem resistant strains. Adverse effects including rise in serum creatinine or neurotoxicity were seen in none.

***Conclusion.*** The study demonstrates excellent safety of colistin even in extremely low birth weight babies. The clinical outcomes were excellent though documented infection with carbapenem resistant strains was seen in only 25% (8/32) of study subjects and use was empirical in around 50%.
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